Ask about this productRelated genes to: PVRIG antibody
- Gene:
- PVRIG NIH gene
- Name:
- PVR related immunoglobulin domain containing
- Previous symbol:
- -
- Synonyms:
- MGC2463, C7orf15, CD112R
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-09-20
- Date modifiied:
- 2017-09-14
Related products to: PVRIG antibody
Related articles to: PVRIG antibody
- Nectin and nectin-like proteins are cell adhesion molecules belonging to the immunoglobulin superfamily that also play a crucial role in the process of immune modulation by interacting with immune receptors like TIGIT, DNAM-1, CD96 and PVRIG. Nectin-4 is a tumour-specific antigen that interacts exclusively with the inhibitory immune receptor TIGIT, resulting in inhibition of NK-cell cytotoxicity and facilitating the process of immune evasion by the cancer cells in the tumour microenvironment. Therefore, deciphering the molecular and structural mechanisms underlying this novel interaction can provide insights for the development of targeted immunotherapeutic interventions. In this study, using structure-guided mutagenesis studies, a novel TIGIT mutant is engineered exhibiting enhanced interaction affinity towards nectin-4 and reduced binding to other TIGIT ligands, such as PVR and nectin-2, which, in contrast to nectin-4, are predominantly expressed on healthy cells. Surface plasmon resonance-based biophysical studies were done to characterize and compare the interaction kinetics of the wild-type (WT) and the engineered mutant TIGIT ectodomains with their ligands. We have shown how a single point mutation of an amino acid residue located in the centre of the F strand of TIGIT dictates its interaction affinity with its ligand. These findings can provide a framework for the development of small-sized non-antibody therapeutics specifically targeted towards nectin-4 overexpressing cancer cells with minimal off-target effects on healthy cells. - Source: PubMed
Ganguli NamrataShaw SayantanSarkar SohiniGoswami SaumyadeepMukherjee GayatriSamanta Dibyendu - Bone metastasis (BoM) is a frequent complication of solid tumors, leading to poor prognosis and reduced survival. CD103⁺ tumor-infiltrating lymphocytes (TILs) are critical for antitumor immunity, yet studies have largely focused on CD8⁺ subsets, leaving CD103⁺CD4⁺ cells poorly characterized. - Source: PubMed
Publication date: 2026/01/02
Brauneck EliasKylies JulianAssemissen Anne MarieKruppa MoritzKruppa NiklasWahid YaganaBrauneck FranziskaFiedler WalterViezens LennartWellbrock JasminLeonhardt Leon-Gordian - Nectins and Nectin-like (Necl) proteins, a family of immunoglobulin-like cell adhesion molecules, are increasingly recognized for their dysregulated expression and aberrant functions in malignancies. They exert dual roles in cancer: promoting tumor progression (proliferation, invasion, metastasis, chemoresistance) through tumor-intrinsic and microenvironment-mediated mechanisms and facilitating immune evasion by engaging checkpoint receptors (TIGIT, CD96, PVRIG) on cytotoxic lymphocytes. Consequently, Nectins have emerged as critical therapeutic targets for modulating both tumor biology and the immune microenvironment. Recent therapeutic advances, particularly Nectin-4-targeted ADCs, anti-TIGIT ICIs, and bispecific antibodies (BsAbs), underscore their clinical promise. This review integrates current understanding of Nectin family members in oncogenesis and immunoregulation, focusing on their biological functions, mechanisms of immune modulation, therapeutic strategies, and remaining challenges in clinical translation. - Source: PubMed
Publication date: 2025/11/28
Chen RongtaoChen WanyueWang RuoyuTao ShuaiLi XiangLiang Shanshan - We investigated a novel therapeutic approach to glioblastoma (GBM) that targets cell-free chromatin particles (cfChPs) that are released from dying GBM cells and aggravate the oncogenic phenotype of living GBM cells. cfChPs can be deactivated by oxygen radicals (OR) generated upon oral administration of the nutraceuticals Resveratrol (R) and Copper (Cu). - Source: PubMed
Publication date: 2025/09/30
Bandiwadekar ChaitraNaorem Leimarembi DeviMoiyadi Aliasgar VSingh VikasShetty PrakashEpari SridharTandel HarshaliYelukar RoohiPoojary DishaRaghuram Gorantla VShabrish SnehalChandrani PratikMittra Indraneel - Preeclampsia is characterized by hypertension and proteinuria after the 20th week of pregnancy. The disease is divided into early and late onset according to the time of diagnosis. Early onset preeclampsia (EOP) develops after the 20th week of pregnancy. The late-onset form usually occurs after the 34th week of pregnancy. TIGIT and PVRIG are immune checkpoint inhibitor receptors. PVRIG binds only to the PVRL2 (nectin-2, CD112). TIGIT binds to both CD112 and CD155. In our study, the control group consisted of placentas from healthy pregnant women, the early onset preeclampsia group (EOP) consisted of patients diagnosed before the 34th week, and the late-onset preeclampsia group (LOP) consisted of placentas from patients diagnosed at or after the 34th week. TIGIT, PVRIG, CD155, and CD112 expression in placental materials was evaluated both immunohistochemically and by RT-PCR. As a result of H scoring of immunohistochemical expression, it was observed that CD112 and CD155 expression decreased and PVRIG expression increased when the EOP and LOP groups were compared with the control group. In the early onset preeclampsia group, CD112, CD155, TIGIT, and PVRIG gene expression increased twofold compared to that in the control group. In the late-onset preeclampsia group, the expression of all the genes decreased to one-third. The results of our study revealed that these genes may serve as biomarkers for early- and late-onset preeclampsia. Detailed studies are required to determine the use of these receptors in the diagnosis and treatment of the disease. - Source: PubMed
Publication date: 2025/05/28
Çetin HülyaLafcı İlknurArman Karakaya YelizEr Urgancı BuketKoşar Can Özlem